[The surgeon and anti-angiogenics].
The surgeon must know the importance of angiogenesis in wound healing. He must also use anti-angiogenics to change the clinical situations and make curative a potentially ineffective surgery. However, these strategies require daily biological indicators able to quantify the tissue activity, that we do not possess yet, nor have we any indicator to predict tumour sensitivity to anti-angiogenics.
Pocard
Marc
M
INSERM U965, Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Université Paris-Diderot/Paris VII, 8 rue Guy Patin, 75475 Paris Cedex 10, France. marc.pocard@1rb.aphp.fr
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D003131:Combined Modality Therapy; D016903:Drug Monitoring; D013502:General Surgery; D006801:Humans; D008113:Liver Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000601:surgery; D008115:Liver Regeneration / Q000187:drug effects; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000235:genetics / Q000532:radiotherapy / Q000601:surgery*; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000235:genetics; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D011878:Radiotherapy / Q000009:adverse effects; D018570:Risk Assessment; D014945:Wound Healing / Q000187:drug effects*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents